Toronto, Ontario March 30, 2021 — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce that its wholly-owned subsidiary Collection Sites, LLC has signed an agreement with Transplant Genomics to offer free COVID-19 PCR tests at its mobile testing centres. As part of the United States’ Health Resources & Services Administration (HRSA) program, testing laboratories can be reimbursed $75-100 per PCR test for services offered to uninsured or undocumented individuals. As part of the agreement, Collection Sites will net a set collection fee per PCR test.
“As the government funded COVID-19 testing programs evolve, it is important that Collection Sties utilize its network of testing sites to particpate in these programs.” comments Medivolve CEO, Doug Sommerville. “We are excited to be able to offer this important testing service to demographics that may not normally have access to these services.”
The free PCR tests will first be rolled out at Collection Sites in California starting this week. Collection Sites will strive to offer patients 24-hour PCR results as part of the HRSA program. The partner lab, Transplant Genomics Inc., is a CLIA-certified high-complexity lab based in Fremont, California and part of the Eurofins Scientific laboratory network.
About the Collection Sites
The mobile testing sites are managed by Las Vegas based company Collection Sites, LLC and powered a CLIA-certified laboratory based in California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.
Wide scale testing will help to bring life back to normal.
The testing centers offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.
For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.
About Medivolve Inc.
Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.
Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.
Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.
For additional information, please contact:
Doug Sommerville, CEO
For investing inquiries please contact:
For US media enquires please contact:
Cautionary Note Regarding Forward-looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the HRSA program; projected timelines for testing results; projected revenues from the testing and reimbursement from HRSA; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE NEO STOCK EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.